Ubs Asset Management Americas Inc Biotechnology

Ubs Asset Management Americas Inc

$446 Billion
Q3 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
VRTX Vertex Pharmaceuticals Inc	$111B	$1.13 Billion 0.25% of portfolio	2,887,117	Q3 2025 Reduced 5.88%
REGN Regeneron Pharmaceuticals, Inc.	$74.3B	$418 Million 0.09% of portfolio	744,173	Q3 2025 Reduced 13.51%
ALNY Alnylam Pharmaceuticals, Inc.	$55.3B	$323 Million 0.07% of portfolio	708,564	Q3 2025 Reduced 26.06%
INCY Incyte Corp	$23.2B	$128 Million 0.03% of portfolio	1,503,585	Q3 2025 Reduced 23.7%
RPRX Royalty Pharma PLC	$17.1B	$110 Million 0.02% of portfolio	3,129,936	Q3 2025 Reduced 23.23%
UTHR United Therapeutics Corp	$21.2B	$85.2 Million 0.02% of portfolio	203,193	Q3 2025 Reduced 28.72%
DNLI Denali Therapeutics Inc.	$2.34B	$79.4 Million 0.02% of portfolio	5,465,037	Q3 2025 Reduced 12.73%
IONS Ionis Pharmaceuticals Inc	$10.2B	$75.5 Million 0.02% of portfolio	1,154,166	Q3 2025 Added 45.9%
INSM Insmed Inc	$26.2B	$73.8 Million 0.02% of portfolio	512,749	Q3 2025 Reduced 26.33%

LGND Ligand Pharmaceuticals Inc	$3.39B	$66.7 Million 0.01% of portfolio	376,601	Q3 2025 Reduced 3.88%
ARWR Arrowhead Pharmaceuticals, Inc.	$4.37B	$60.7 Million 0.01% of portfolio	1,759,489	Q3 2025 Reduced 34.45%
BMRN Biomarin Pharmaceutical Inc	$10.2B	$58.2 Million 0.01% of portfolio	1,074,173	Q3 2025 Reduced 18.61%
MRNA Moderna, Inc.	$9.69B	$50.7 Million 0.01% of portfolio	1,960,968	Q3 2025 Reduced 35.14%
KYMR Kymera Therapeutics, Inc.	$3.55B	$48.9 Million 0.01% of portfolio	863,762	Q3 2025 Added 5.47%
RYTM Rhythm Pharmaceuticals, Inc.	$5.54B	$44.2 Million 0.01% of portfolio	437,472	Q3 2025 Added 92.19%
BEAM Beam Therapeutics Inc.	$1.55B	$40.4 Million 0.01% of portfolio	1,665,385	Q3 2025 Added 237.53%
KRYS Krystal Biotech, Inc.	$5.29B	$35.8 Million 0.01% of portfolio	202,589	Q3 2025 Reduced 13.54%
ROIV Roivant Sciences Ltd.	$14.3B	$32.1 Million 0.01% of portfolio	2,123,617	Q3 2025 Reduced 23.48%

EXEL Exelixis, Inc.	$13.4B	$31 Million 0.01% of portfolio	751,613	Q3 2025 Reduced 33.84%
TECH Bio Techne Corp	$2.33B	$30.9 Million 0.01% of portfolio	555,932	Q3 2025 Reduced 32.05%
BBIO Bridge Bio Pharma, Inc.	$9.84B	$26.7 Million 0.01% of portfolio	513,263	Q3 2025 Reduced 27.13%
HALO Halozyme Therapeutics, Inc.	$9.75B	$24 Million 0.01% of portfolio	326,967	Q3 2025 Reduced 34.12%
JAZZ Jazz Pharmaceuticals PLC	$8.84B	$22.4 Million 0.01% of portfolio	169,687	Q3 2025 Reduced 38.08%
RXRX Recursion Pharmaceuticals, Inc.	$747M	$20.5 Million 0.0% of portfolio	4,196,978	Q3 2025 Reduced 9.07%
CORT Corcept Therapeutics Inc	$8.09B	$16.8 Million 0.0% of portfolio	202,729	Q3 2025 Reduced 38.68%
RVMD Revolution Medicines, Inc.	$5.94B	$15.9 Million 0.0% of portfolio	341,367	Q3 2025 Reduced 31.82%
PCVX Vaxcyte, Inc.	$2.87B	$14.3 Million 0.0% of portfolio	398,144	Q3 2025 Reduced 28.26%
ACLX Arcellx, Inc.	$3.94B	$13.8 Million 0.0% of portfolio	168,631	Q3 2025 Reduced 36.87%
CYTK Cytokinetics Inc	$6.25B	$13.1 Million 0.0% of portfolio	238,382	Q3 2025 Reduced 42.73%
MDGL Madrigal Pharmaceuticals, Inc.	$9.05B	$10.8 Million 0.0% of portfolio	23,476	Q3 2025 Reduced 41.03%
AXSM Axsome Therapeutics, Inc.	$5.99B	$10.5 Million 0.0% of portfolio	86,691	Q3 2025 Reduced 35.35%
CRNX Crinetics Pharmaceuticals, Inc.	$2.34B	$9.07 Million 0.0% of portfolio	217,690	Q3 2025 Reduced 34.98%
TGTX Tg Therapeutics, Inc.	$4.5B	$8.85 Million 0.0% of portfolio	245,051	Q3 2025 Reduced 40.14%
PTCT Ptc Therapeutics, Inc.	$5.39B	$7.97 Million 0.0% of portfolio	129,898	Q3 2025 Reduced 43.44%
RNA Avidity Biosciences, Inc.	$3.69B	$7.58 Million 0.0% of portfolio	173,995	Q3 2025 Reduced 56.06%
PTGX Protagonist Therapeutics, Inc	$4.15B	$7.32 Million 0.0% of portfolio	110,229	Q3 2025 Reduced 54.71%
VCYT Veracyte, Inc.	$2.82B	$6.88 Million 0.0% of portfolio	200,433	Q3 2025 Reduced 41.73%
FOLD Amicus Therapeutics, Inc.	$2.66B	$6.48 Million 0.0% of portfolio	822,931	Q3 2025 Reduced 34.47%
RARE Ultragenyx Pharmaceutical Inc.	$2.32B	$6.23 Million 0.0% of portfolio	207,042	Q3 2025 Reduced 31.21%
VKTX Viking Therapeutics, Inc.	$3.05B	$6.23 Million 0.0% of portfolio	243,766	Q3 2025 Reduced 52.12%
ADMA Adma Biologics, Inc.	$3.06B	$5.73 Million 0.0% of portfolio	390,828	Q3 2025 Reduced 58.55%
NUVL Nuvalent, Inc.	$4.15B	$5.66 Million 0.0% of portfolio	65,417	Q3 2025 Reduced 61.41%
IDYA Ideaya Biosciences, Inc.	$1.54B	$5.48 Million 0.0% of portfolio	201,443	Q3 2025 Reduced 26.12%
CPRX Catalyst Pharmaceuticals, Inc.	$2.38B	$5.46 Million 0.0% of portfolio	277,301	Q3 2025 Reduced 52.65%
AKRO Akero Therapeutics, Inc.	$2.52B	$4.74 Million 0.0% of portfolio	99,917	Q3 2025 Reduced 38.16%
ARQT Arcutis Biotherapeutics, Inc.	$1.5B	$4.6 Million 0.0% of portfolio	244,015	Q3 2025 Reduced 39.71%
ACAD Acadia Pharmaceuticals Inc	$3.89B	$4.51 Million 0.0% of portfolio	211,115	Q3 2025 Reduced 38.43%
SRPT Sarepta Therapeutics, Inc.	$1.65B	$4.5 Million 0.0% of portfolio	233,461	Q3 2025 Reduced 41.07%
MIRM Mirum Pharmaceuticals, Inc.	$2.63B	$4.45 Million 0.0% of portfolio	60,699	Q3 2025 Reduced 62.41%
AGIO Agios Pharmaceuticals, Inc.	$2.39B	$4.29 Million 0.0% of portfolio	106,875	Q3 2025 Reduced 50.84%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.